Metformin attenuates cells stemness and epithelial‑mesenchymal transition in colorectal cancer cells by inhibiting the Wnt3a/β‑catenin pathway

Zhang,Chu; Wang,Yuchen

doi:10.3892/mmr.2018.9765

Metformin attenuates cells stemness and epithelial‑mesenchymal transition in colorectal cancer cells by inhibiting the Wnt3a/β‑catenin pathway

Authors:
- Chu Zhang
- Yuchen Wang
View Affiliations

Affiliations: Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, P.R. China, Department of Orthopedics, Wujin Traditional Chinese Medicine Hospital Affiliated to Nanjing University of Chinese Medicine, Changzhou, Jiangsu 213161, P.R. China
Published online on: December 14, 2018 https://doi.org/10.3892/mmr.2018.9765
Pages: 1203-1209
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to examine the roles and mechanisms of metformin in the stemness and epithelial‑mesenchymal transition (EMT) of colorectal cancer cells. The formation of spheroid cells, and the results of reverse transcription‑quantitative polymerase chain reaction and western blot analyses showed that metformin suppressed the ability to form spheroid cells and the expression of stemness markers in HCT116 colorectal cancer cells. Additionally, metformin attenuated the EMT process, characterized by a decrease of mesenchymal marker Vimentin and an increase in the expression of an epithelial marker. Mechanistically, metformin inactivated the Wnt3a/β‑catenin signaling pathway, and reactivation of Wnt3a/β‑catenin signaling attenuated the inhibition of metformin on the stemness of HCT116 colorectal cancer cells and EMT. Finally, it was revealed that metformin re‑sensitized HCT116 sphere cells to 5‑fluorouracil resistance. These results suggest that metformin can attenuate stemness and EMT in colorectal cancer cells.

View Figures

View References

1	Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH and Huang YC: Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: A representative population prospective cohort study of 800,000 individuals. BMC Cancer. 11:202011. View Article : Google Scholar : PubMed/NCBI
2	Lee JH, Kim TI, Jeon SM, Hong SP, Cheon JH and Kim WH: The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer. 131:752–759. 2012. View Article : Google Scholar : PubMed/NCBI
3	Wang N, Docherty F, Brown HK, Reeves K, Fowles A, Lawson M, Ottewell PD, Holen I, Croucher PI and Eaton CL: Mitotic quiescence, but not unique ‘stemness,’ marks the phenotype of bone metastasis-initiating cells in prostate cancer. FASEB J. 29:3141–3150. 2015. View Article : Google Scholar : PubMed/NCBI
4	Mukherjee S, Manna A, Bhattacharjee P, Mazumdar M, Saha S, Chakraborty S, Guha D, Adhikary A, Jana D, Gorain M, et al: Non-migratory tumorigenic intrinsic cancer stem cells ensure breast cancer metastasis by generation of CXCR4(+) migrating cancer stem cells. Oncogene. 35:4937–4948. 2016. View Article : Google Scholar : PubMed/NCBI
5	Saha S, Mukherjee S, Khan P, Kajal K, Mazumdar M, Manna A, Mukherjee S, De S, Jana D, Sarkar DK and Das T: Aspirin suppresses the acquisition of chemoresistance in breast cancer by disrupting an NFκB-IL6 signaling axis responsible for the generation of cancer stem cells. Cancer Res. 76:2000–2012. 2016. View Article : Google Scholar : PubMed/NCBI
6	Suwei D, Liang Z, Zhimin L, Ruilei L, Yingying Z, Zhen L, Chunlei G, Zhangchao L, Yuanbo X, Jinyan Y, et al: NLK functions to maintain proliferation and stemness of NSCLC and is a target of metformin. J Hematol Oncol. 8:1202015. View Article : Google Scholar : PubMed/NCBI
7	Yuan X, Wei W, Bao Q, Chen H, Jin P and Jiang W: Metformin inhibits glioma cells stemness and epithelial-mesenchymal transition via regulating YAP activity. Biomed Pharmacother. 102:263–270. 2018. View Article : Google Scholar : PubMed/NCBI
8	Zhang L, Wang H, Li C, Zhao Y, Wu L, Du X and Han Z: VEGF-A/neuropilin 1 pathway confers cancer stemness via activating Wnt/β-catenin axis in breast cancer cells. Cell Physiol Biochem. 44:1251–1262. 2017. View Article : Google Scholar : PubMed/NCBI
9	Zhang K, Guo Y, Wang X, Zhao H, Ji Z, Cheng C, Li L, Fang Y, Xu D, Zhu HH and Gao WQ: WNT/β-catenin directs self-renewal symmetric cell division of hTERT^high prostate cancer stem cells. Cancer Res. 77:2534–2547. 2017. View Article : Google Scholar : PubMed/NCBI
10	Garikapati KR, Patel N, Makani VKK, Cilamkoti P, Bhadra U and Bhadra MP: Down-regulation of BORIS/CTCFL efficiently regulates cancer stemness and metastasis in MYCN amplified neuroblastoma cell line by modulating Wnt/β-catenin signaling pathway. Biochem Biophys Res Commun. 484:93–99. 2017. View Article : Google Scholar : PubMed/NCBI
11	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−ΔΔC(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
12	Kida K, Ishikawa T, Yamada A, Shimada K, Narui K, Sugae S, Shimizu D, Tanabe M, Sasaki T, Ichikawa Y and Endo I: Effect of ALDH1 on prognosis and chemoresistance by breast cancer subtype. Breast Cancer Res Treat. 156:261–269. 2016. View Article : Google Scholar : PubMed/NCBI
13	Ren D, Zhu X, Kong R, Zhao Z, Sheng J, Wang J, Xu X, Liu J, Cui K, Zhang XH, et al: Targeting brain-adaptive cancer stem cells prohibits brain metastatic colonization of triple-negative breast cancer. Cancer Res. 78:2052–2064. 2018. View Article : Google Scholar : PubMed/NCBI
14	Xu S, Yang Z, Jin P, Yang X, Li X, Wei X, Wang Y, Long S, Zhang T, Chen G, et al: Metformin suppresses tumor progression by inactivating stromal fibroblasts in ovarian cancer. Mol Cancer Ther. 17:1291–1302. 2018. View Article : Google Scholar : PubMed/NCBI
15	Lee JE, Lim JH, Hong YK and Yang SH: High-dose metformin plus temozolomide shows increased anti-tumor effects in glioblastoma in vitro and in vivo compared with monotherapy. Cancer Res Treat. 50:1331–1342. 2018. View Article : Google Scholar : PubMed/NCBI
16	Tian Y, Tang B, Wang C, Sun D, Zhang R, Luo N, Han Z, Liang R, Gao Z and Wang L: Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP. Oncotarget. 7:46230–46241. 2016. View Article : Google Scholar : PubMed/NCBI
17	Cheng G and Lanza-Jacoby S: Metformin decreases growth of pancreatic cancer cells by decreasing reactive oxygen species: Role of NOX4. Biochem Biophys Res Commun. 465:41–46. 2015. View Article : Google Scholar : PubMed/NCBI
18	Liu Y, He C and Huang X: Metformin partially reverses the carboplatin-resistance in NSCLC by inhibiting glucose metabolism. Oncotarget. 8:75206–75216. 2017.PubMed/NCBI